Please assess the completion status of the following clinical trial:

Trial Title: Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Either sex~* Liver resection deemed clinically appropriate for management of metastatic colorectal cancer~* Duration between decision to perform liver resection and surgery greater than 2 weeks~* Ability to give written informed consent and follow study protocol~* Telephone contact possible~Exclusion Criteria:~* Neo-adjuvant chemotherapy for colorectal cancer (CRC) liver metastasis~* Chemotherapy for any cancer in the previous 3 months~* Known bleeding diathesis or anticoagulation therapy~* Fish or seafood allergy~* Use of fish oil supplements (eg. cod liver oil) and unwilling to stop for the duration of the study~* Pregnancy~* Non-aspirin non-steroidal anti-inflammatory (NSAID) or corticosteroid use~* Renal impairment (serum creatinine \>150)~* Active inflammatory disease (e.g. Inflammatory Bowel Disease, Rheumatoid Arthritis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 2 capsules twice daily
- Eicosapentaenoic acid free fatty acid (Type: ACTIVE_COMPARATOR): 2g daily (2 x 500mg capsules twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).